Recent News

September 19, 2019 at 4:05 PM EDT

Summary Toggle Proteostasis Therapeutics Announces Presentation at the UK Cystic Fibrosis Conference

BOSTON , Sept.19, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
August 7, 2019 at 4:05 PM EDT

Summary Toggle Proteostasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

BOSTON , Aug. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
July 25, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics Initiates Dosing in Global Phase 2 Study in Cystic Fibrosis

BOSTON , July 25, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that the first patient has been dosed in the
July 23, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics Announces Management Changes and Appointments

Geoffrey S. Gilmartin, MD, MMSc, to Succeed Po-Shun Lee, MD as Chief Medical Officer; Dr. Lee to Remain a Consultant for the Company Andrey E. Belous, MD, PhD, Appointed as Senior Medical Director, Joining From Galapagos NV BOSTON , July 23, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc.
June 4, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 for the Treatment of Cystic Fibrosis

BOSTON , June 4, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
June 3, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics Announces Presentations and Hosts Educational Symposium at the 42nd European Cystic Fibrosis Conference

BOSTON , June 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
May 15, 2019 at 8:00 AM EDT

Summary Toggle Proteostasis Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

BOSTON , May 15, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
May 13, 2019 at 8:00 AM EDT

Summary Toggle Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors

BOSTON , May 13, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
May 8, 2019 at 5:15 PM EDT

Summary Toggle Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

BOSTON , May 8, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
March 25, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients

Greatest ppFEV1 Improvement Shown in High Dose Triplet with Mean Absolute Improvement in ppFEV1 of 8 Percentage Points at 14 Days Compared to Placebo (p